These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
198 related articles for article (PubMed ID: 11793163)
1. COMT-inhibition increases serum levels of dihydroxyphenylacetic acid (DOPAC) in patients with advanced Parkinson's disease. Oechsner M; Buhmann C; Strauss J; Stuerenburg HJ J Neural Transm (Vienna); 2002; 109(1):69-75. PubMed ID: 11793163 [TBL] [Abstract][Full Text] [Related]
2. Effects of the catechol-O-methyltransferase inhibitor tolcapone in Parkinson's disease: correlations between concentrations of dopaminergic substances in the plasma and cerebrospinal fluid and clinical improvement. Tohgi H; Abe T; Yamazaki K; Saheki M; Takahashi S; Tsukamoto Y Neurosci Lett; 1995 Jun; 192(3):165-8. PubMed ID: 7566641 [TBL] [Abstract][Full Text] [Related]
3. Effects of tolcapone, a catechol-O-methyltransferase inhibitor, on motor symptoms and pharmacokinetics of levodopa in patients with Parkinson's disease. Yamamoto M; Yokochi M; Kuno S; Hattori Y; Tsukamoto Y; Narabayashi H; Tohgi H; Mizuno Y; Kowa H; Yanagisawa N; Kanazawa I J Neural Transm (Vienna); 1997; 104(2-3):229-36. PubMed ID: 9203084 [TBL] [Abstract][Full Text] [Related]
4. Acute administration of levodopa-benserazide and tolcapone, a COMT inhibitor, Parkinson's disease. Limousin P; Pollak P; Pfefen JP; Tournier-Gervason CL; Dubuis R; Perret JE Clin Neuropharmacol; 1995 Jun; 18(3):258-65. PubMed ID: 8635184 [TBL] [Abstract][Full Text] [Related]
5. Tolcapone decreases plasma levels of S-adenosyl-L-homocysteine and homocysteine in treated Parkinson's disease patients. Müller T; Kuhn W Eur J Clin Pharmacol; 2006 Jun; 62(6):447-50. PubMed ID: 16758261 [TBL] [Abstract][Full Text] [Related]
6. The relationship between COMT genotype and the clinical effectiveness of tolcapone, a COMT inhibitor, in patients with Parkinson's disease. Chong DJ; Suchowersky O; Szumlanski C; Weinshilboum RM; Brant R; Campbell NR Clin Neuropharmacol; 2000; 23(3):143-8. PubMed ID: 10895397 [TBL] [Abstract][Full Text] [Related]
7. Fewer fluctuations, higher maximum concentration and better motor response of levodopa with catechol-O-methyltransferase inhibition. Muhlack S; Herrmann L; Salmen S; Müller T J Neural Transm (Vienna); 2014 Nov; 121(11):1357-66. PubMed ID: 24770794 [TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetic-pharmacodynamic modeling of levodopa in patients with advanced Parkinson disease. Adamiak U; Kaldonska M; Klodowska-Duda G; Wyska E; Safranow K; Bialecka M; Gawronska-Szklarz B Clin Neuropharmacol; 2010 May; 33(3):135-41. PubMed ID: 20216409 [TBL] [Abstract][Full Text] [Related]
9. COMT inhibition in the treatment of Parkinson's disease. Ruottinen HM; Rinne UK J Neurol; 1998 Nov; 245(11 Suppl 3):P25-34. PubMed ID: 9808337 [TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetic-pharmacodynamic relationship of levodopa with and without tolcapone in patients with Parkinson's disease. Baas H; Zehrden F; Selzer R; Kohnen R; Loetsch J; Harder S Clin Pharmacokinet; 2001; 40(5):383-93. PubMed ID: 11432539 [TBL] [Abstract][Full Text] [Related]
11. Catechol-O-methyltransferase inhibitors for levodopa-induced complications in Parkinson's disease. Deane KH; Spieker S; Clarke CE Cochrane Database Syst Rev; 2004 Oct; 2004(4):CD004554. PubMed ID: 15495119 [TBL] [Abstract][Full Text] [Related]
12. Catechol-O-methyltransferase inhibition with tolcapone reduces the "wearing off" phenomenon and levodopa requirements in fluctuating parkinsonian patients. Baas H; Beiske AG; Ghika J; Jackson M; Oertel WH; Poewe W; Ransmayr G J Neurol Neurosurg Psychiatry; 1997 Oct; 63(4):421-8. PubMed ID: 9343116 [TBL] [Abstract][Full Text] [Related]
13. Modifications of plasma and platelet levels of L-DOPA and its direct metabolites during treatment with tolcapone or entacapone in patients with Parkinson's disease. Blandini F; Nappi G; Fancellu R; Mangiagalli A; Samuele A; Riboldazzi G; Calandrella D; Pacchetti C; Bono G; Martignoni E J Neural Transm (Vienna); 2003 Aug; 110(8):911-22. PubMed ID: 12898346 [TBL] [Abstract][Full Text] [Related]
14. COMT inhibition by tolcapone further improves levodopa pharmacokinetics when combined with a dual-release formulation of levodopa/benserazide. A novel principle in the treatment of Parkinson's disease. Gasser UE; Jorga K; Crevoisier C; Hovens SE; van Giersbergen PL Eur Neurol; 1999; 41(4):206-11. PubMed ID: 10343151 [TBL] [Abstract][Full Text] [Related]
15. Influence of COMT inhibition on levodopa pharmacology and therapy. Goetz CG Neurology; 1998 May; 50(5 Suppl 5):S26-30. PubMed ID: 9591519 [TBL] [Abstract][Full Text] [Related]
16. Catechol-O-methyltransferase inhibitors versus active comparators for levodopa-induced complications in Parkinson's disease. Deane KH; Spieker S; Clarke CE Cochrane Database Syst Rev; 2004 Oct; 2004(4):CD004553. PubMed ID: 15495118 [TBL] [Abstract][Full Text] [Related]
17. Clinical, pharmacokinetic, and pharmacodynamic effects of tolcapone withdrawal in levodopa-treated patients with parkinsonism. Jorga KM; Davis TL; Kurth MC; Saint-Hilaire MH; LeWitt PA; Fotteler B; Zürcher G; Rabbia M Clin Neuropharmacol; 2000; 23(2):98-105. PubMed ID: 10803800 [TBL] [Abstract][Full Text] [Related]
19. Population pharmacokinetics of levodopa in patients with Parkinson's disease treated with tolcapone. Jorga K; Banken L; Fotteler B; Snell P; Steimer JL Clin Pharmacol Ther; 2000 Jun; 67(6):610-20. PubMed ID: 10872643 [TBL] [Abstract][Full Text] [Related]
20. Tolcapone: a review of its use in the management of Parkinson's disease. Keating GM; Lyseng-Williamson KA CNS Drugs; 2005; 19(2):165-84. PubMed ID: 15697329 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]